chloroquine/lafyèv

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 59 rezilta yo

Northeast COVID-19 and Pregnancy Study Group

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

General Objective: To determine the frequency of COVID-19 in pregnant and postpartum women admitted with flu syndrome, to evaluate the clinical and laboratory predictors of COVID-19 progression and to identify the factors associated with adverse maternal and perinatal / neonatal outcomes in six

Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In December, 2019, an outbreak of pneumonia with unknown cause occurred in Wuhan city, the capital of Hubei province in China. On January 7th, the scientists succeeded to isolate a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). WHO nominated it as coronavirus

Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

More cases of COVID-19 pandemic are being reported daily around the world. It is highly infectious and, over 7 million people have been infected and more than 400,000 people have died globally till this date. Countries around the world are struggling to avoid the spread of this pandemic. The most

A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This study was done from May 2nd to June 5th, 2020. The investigators included 181 patients who were tested positive for SARS-CoV-2 infection by RT PCR presented and the sample collected at Chokoria Upazila Health Complex, Cox's Bazar; Bangladesh. The PCR analysis of the collected sample was done at

Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background On February 21th 2020, SARS-CoV-2 outbreak erupted in Italy and, in the immediately subsequent period, all the Italian regional Health Systems had to face with an overwhelming increase of COVID-19 admissions requiring isolation, oxygen, ventilation and ICU beds. The COVID-19 related

Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background and rational of the study: Novel corona virus (SARS-CoV-2) epidemic which stared from Wuhan in China is now a well established pandemic worldwide affecting more than 3 lakh people with more than 15000 mortality. As Italy, Spain, Germany, United Kingdom and USA have taken over from China

Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Recruitment Details. The investigator enrolled, in the study, subjects with COVID-19 modest to moderate respiratory insufficiency (SIMEU clinical phenotypes 2-4) thus cared in an infectious disease ward. To note that The Italian Society of Emergency and Urgency Medicine (SIMEU - Società Italiana di

Favipiravir vs Hydroxychloroquine in COVID -19

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) and has developed into a pandemic with serious global public health and economic sequelae As of April 27, 2020 over 2,973,000 cases have been confirmed worldwide leading to

COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Since the first case of Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) infection and its subsequent clinical manifestation (COronaVIrus Disease 19, COVID-19) in the city of Wuhan (Hubei, China) in December 2019, contagion abruptly spread to different regions of China

Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Dialyzable Leukocyte Extract (DLE) (Transferon oral®) is a dialyzed extract obtained from human leukocytes. Its active ingredient is a complex mixture of low molecular weight peptides obtained from dialysis (12 kDa), and subsequent ultrafiltration (10 kDa) of lysed leukocyte and platelet

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients (SnPPIX) Official Title: Efficacy of Based MRI Contrast Media Against Covid-19 _____________________________________________________________________________________________

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

SARS-CoV-2 is a novel coronavirus disease (COVID-19) that presents with fever, cough, and shortness of breath, and has a mortality rate of 2-4%. Outcomes are worse among the elderly and those with cardiovascular, respiratory, cancer and other co-morbidities. Several treatments are also emerging as

COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Design: Retrospective cohort study that will review the data of patients seen in participating centers with a confirmed or probable diagnosis of COVID-19 between March and April 2020. Those patients who test positive for nasopharyngeal exudate for SARS-CoV-2 will be considered a confirmed case using

Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

STUDY OBJECTIVE The objective of the study is to estimate the frequency of cardiac arrhythmias and characterize the mode of death in patients with the novel coronavirus disease (SARS-CoV-2; COVID-19). INTRODUCTION, RATIONALE The novel coronavirus (SARS-CoV-2) emerged in Wuhan, China, in late 2019

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye